Zyvana MV 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride (2mg), Metformin (500mg), and Voglibose (0.2mg), formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, mitigating postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged drug release, promoting better patient compliance and stable plasma drug concentrations. Zyvana MV 2 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or on monotherapy, providing a multifaceted approach to glycemic management by targeting different pathophysiological mechanisms of type 2 diabetes. It should be used under medical supervision with appropriate lifestyle modifications. Caution is advised in patients with renal or hepatic impairment, and hypoglycemia risk should be monitored, especially when combined with other antidiabetic agents. Regular blood glucose monitoring and periodic assessment of renal function are recommended during therapy.